This site has been produced by Kite, a Gilead Company

Cytokine release syndrome (CRS)

Cytokine Release Syndrome (CRS) is a common side effect of CAR T-cell therapy and is related to the way the treatment works.

It occurs when CAR T-cells cause the body to have an inflammatory response. The body releases large amounts of cytokines (proteins) into the bloodstream from immune cells affected by the treatment.

It’s important to receive treatment for CRS as soon as possible. Your healthcare team will monitor you closely and will help to identify if you are having a reaction. If you do experience more severe side effects, you may be moved to the Intensive Care Unit (ICU) to ensure you get the best possible care. More information on the ICU can be found here.

With treatment, the majority of patients are successfully treated for CRS.

Tell your doctor or healthcare team straight away if you notice any of the following signs and symptoms:

Bullet
Fever (e.g., temperature above 38°C)
Bullet
Light-headedness
Bullet
Dizziness
Bullet
Low blood pressure
Bullet
Shortness of breath
Bullet
Rapid heartbeat
Bullet
Chills
Bullet
Extreme tiredness
Bullet
Weakness
Bullet
Headache
Bullet
Cough

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

United Kingdom: Reporting of side effects

For patients residing in the United Kingdom, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of your medicine.

Republic of Ireland: Reporting of side effects

For patients residing in the Republic of Ireland, you can also report side effects directly via the HPRA website at www.hpra.ie. By reporting side effects, you can help provide more information on the safety of your medicine.

This site is a patient information resource, intended only for patients residing in the United Kingdom and Ireland who are being referred for or have been prescribed CAR T-cell therapy by their healthcare professional. This site has been developed and paid for by Kite, a Gilead Company.

This site has been produced by Kite, a Gilead Company

© 2024 Gilead Sciences, Inc. All rights reserved. KITE and the Kite logo are registered trademarks of Kite Pharma, Inc | GILEAD is a registered trademark of Gilead Sciences, Inc and its related companies

UK-UNB-3795 April 2023